PRECISION BIOLOGICS / RESOURCES

Resources

01 / Vendor evaluation

How clinics evaluate a stem cell supplier (and what the label really means)

↗02 / Vendor evaluation

Wharton's jelly supplier checklist for clinics and medspas

↗03 / Vendor evaluation

Exosome supplier due diligence: 14 documents to request

↗04 / Vendor evaluation

Choosing a regenerative biologics distributor: a buyer's framework

↗05 / Vendor evaluation

How to read a certificate of analysis for perinatal biologics

↗06 / Clinic operations

A vendor qualification SOP template for biologics purchasing

↗07 / Regulatory

Is Wharton's jelly FDA approved? What clinic owners need to know

↗08 / Regulatory

Are exosomes FDA approved? The regulatory position in plain English

↗09 / Regulatory

Section 361 vs 351: how FDA classifies perinatal biologics

↗10 / Regulatory

Homologous use explained: why intended use drives classification

↗11 / Regulatory

What the 2026 FDA warning letters mean for clinics and distributors

↗12 / Regulatory

Is stem cell therapy legal? A clinic owner's regulatory overview

↗13 / Regulatory

State laws and non-FDA-approved therapies: Florida SB 1768 in context

↗14 / Regulatory

Regenerative medicine marketing compliance: what clinics can and cannot say

↗15 / Regulatory

Why 'research use only' disclaimers do not protect clinical-use marketing

↗16 / Regulatory

Google Ads rules for cell therapy advertising and what that means for clinics

↗17 / Regulatory

FTC claim substantiation for clinic marketing of biologics

↗18 / Comparisons

Wharton's jelly vs PRP: composition, preparation and regulatory differences

↗19 / Comparisons

Wharton's jelly vs stem cells: what commercial products actually contain

↗20 / Comparisons

Exosomes vs stem cells: cells, vesicles and the vocabulary that matters

↗21 / Comparisons

PRP, Wharton's jelly, exosomes and amniotic products: comparing documentation by category

↗22 / Science

Mesenchymal stromal cells vs umbilical cord allografts: the live-cell question

↗23 / Science

What is Wharton's jelly? Composition and structure of the umbilical cord matrix

↗24 / Science

What are exosomes? Extracellular vesicles explained for clinic teams

↗25 / Science

MISEV2023 and why 'exosome' is often the wrong word

↗26 / Science

What to request from an EV or exosome supplier: a documentation checklist

↗27 / Science

Umbilical cord stem cells: what peer-reviewed analyses say about commercial products

↗28 / Science

Cell content in commercial Wharton's jelly products: a plain-language digest

↗29 / Science

Colony-forming potential in cord allografts: a 2021 study explained

↗30 / Science

EV characterization methods: NTA, ELISA and SP-IRIS in plain language

↗31 / Clinic operations

Cold chain handling for cryopreserved perinatal biologics: a clinic workflow

↗32 / Clinic operations

Receiving checklist for dry-ice biologics shipments

↗33 / Clinic operations

Lot traceability and record-keeping for perinatal products

↗34 / Clinic operations

Adverse event documentation and reporting for clinics using biologics

↗35 / Clinic operations

Medspa compliance for regenerative biologics: medical director oversight

↗36 / Clinic operations

Insurance and malpractice considerations when adding biologics

↗37 / Clinic operations

Informed consent documentation when a product is not FDA approved

↗38 / Clinic operations

Building a regenerative biologics program: an operations-first roadmap

↗39 / Vendor evaluation

Orthobiologics purchasing for practice managers: a procurement primer

↗40 / Vendor evaluation

How NPI verification works for biologics purchasing accounts

↗41 / Vendor evaluation

30 questions to ask a perinatal biologics supplier before you buy

↗42 / Clinic operations

Cold Chain for Cryopreserved Biologics: A Clinic Buyer's Checklist

↗43 / Regulatory

Building a Compliant Regenerative Marketing Kit for Your Clinic

↗44 / Vendor evaluation

What Clinics Ask Before Ordering Wharton's Jelly Products: A Supplier Checklist

↗45 / Science

What are Wharton's jelly allografts? A clinic procurement brief

↗46 / Regulatory

Section 361 HCT/P: what clinics should document

↗47 / Regulatory

21 CFR Part 1271: a clinic checklist for vendor review

↗48 / Regulatory

Manufacturing arrangements under 21 CFR 1271: clinic questions

↗49 / Comparisons

How clinics compare umbilical cord tissue allograft suppliers

↗50 / Clinic operations

Build a perinatal tissue allograft documentation pack

↗51 / Clinic operations

Cold chain for cryopreserved biologics in clinics

↗52 / Clinic operations

Dry-ice shipping: clinic receiving SOP outline

↗53 / Clinic operations

Lot release and quarantine, explained for clinic buyers

↗54 / Science

Third-party sterility testing: questions clinics should ask

↗55 / Regulatory

Donor eligibility and serology: what clinics can request

↗56 / Vendor evaluation

AATB and AABB: what clinics should ask suppliers

↗57 / Regulatory

Homologous use and when to call clinic counsel

↗58 / Regulatory

Section 351 vs 361: exosome products for clinic buyers

↗59 / Comparisons

Lyophilized vs cryopreserved exosomes: operations comparison

↗60 / Science

Extracellular vesicle vs exosome: procurement language

↗61 / Vendor evaluation

Certificate of analysis red flags for biologics buyers

↗62 / Clinic operations

NPI verification for biologics accounts

↗63 / Clinic operations

Medspa biologics access under physician supervision

↗64 / Vendor evaluation

Orthopedic clinic biologics procurement guide

↗65 / Vendor evaluation

PM&R clinic regenerative biologics sourcing

↗66 / Clinic operations

Pain clinic biologics documentation checklist

↗67 / Vendor evaluation

Functional medicine clinic biologics supplier review

↗68 / Vendor evaluation

Anti-aging clinic biologics procurement (compliance-first)

↗69 / Vendor evaluation

Longevity clinic exosome supplier checklist

↗70 / Regulatory

Aesthetic practice biologics compliance basics

↗71 / Clinic operations

Surgery center biologics logistics

↗72 / Clinic operations

Hospital outpatient biologics vendor packet

↗73 / Clinic operations

How clinics request supporting literature

↗74 / Vendor evaluation

Regenerative biologics RFP template for clinics

↗75 / Comparisons

Comparing Wharton's jelly vial formats (1 mL, 2 mL, 3 mL)

↗76 / Clinic operations

Shelf-stable exosome products: clinic operations notes

↗77 / Regulatory

What not to claim in stem cell marketing

↗78 / Regulatory

Clinic marketing kit compliance checklist

↗79 / Regulatory

Google Ads policies notes for regenerative clinics

↗80 / Regulatory

Informed consent language vs marketing copy

↗81 / Clinic operations

Chain of identity and lot tracking for clinics

↗82 / Clinic operations

Receiving SOP outline for cryopreserved vials

↗83 / Clinic operations

Storage at -80°C: clinic requirements checklist

↗84 / Vendor evaluation

Validating a new biologics vendor

↗85 / Vendor evaluation

Questions for your tissue bank supplier

↗86 / Regulatory

HCT/P small entity compliance guide: clinic takeaways

↗87 / Comparisons

Amniotic vs Wharton's jelly: procurement differences

↗88 / Science

Connective tissue allograft vs scaffold terminology

↗89 / Clinic operations

Clinic onboarding timeline for biologics accounts

↗90 / Clinic operations

Multi-location clinic biologics distribution

↗91 / Clinic operations

How to audit a biologics invoice and COA pack

↗92 / Regulatory

Research-use vs clinical-use labeling

↗93 / Science

Particle count claims: how to read them

↗94 / Science

Growth factor panels are analytical, not clinical

↗95 / Science

C-section donor recovery, explained for clinics

↗96 / Clinic operations

Same-day vs overnight biologics shipping

↗97 / Clinic operations

Backup vial inventory planning for clinics

↗